
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics is a clinical-stage precision medicine company that uses its Dynamo platform to integrate leading-edge computational and experimental approaches for previously untreatable targets. Its initial efficacy data from the dose-escalation study showed a best-in-class safety profile, with a 44% objective response rate and a 77% patient retention rate. With a focus on precision oncology and genetic disease, RLAY has potential for substantial growth in the coming years.
Bears say
Relay Therapeutics is predicted to be a leader in precision medicine, developing a strong pipeline of first-in-class medicines for precision oncology and genetic diseases. However, their early triplet update exhibits superior results compared to their competitors, potentially increasing opportunity in 1L HR+/HER2- metastatic breast cancer and potentially mitigating the risk of their ongoing ReDiscover-2 trial. Furthermore, their sales and marketing and deemed dividend expenses could potentially impact the company's financials and overall outlook.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares